BBC – Virtus LifeSci Biotech Clinical Trials ETF
Virtus LifeSci Biotech Clinical Trials ETF (BBC) is a Health ETF, issued by Virtus, $38.1M in assets, 0.79% expense ratio.
Returns as of Oct 23, 2026: 1 week +5.4%, 1 year +91.7%.
Tracks U.S. biotech companies with lead drugs in clinical trials. Focuses on firms in Phase 1, 2, or 3 stages before marketing approval.
Top holdings
- ERAS – Erasca Inc, 2.1%
- ALMS – Alumis Inc, 1.6%
- VTYX – Ventyx Biosciences Inc, 1.3%
- ELVN – Enliven Therapeutics Inc., 1.2%
- RVMD – Revolution Medicines Inc, 1.2%
- RZLT – Rezolute Inc, 1.2%
- GLUE – Monte Rosa Therapeutics Inc, 1.1%
- BCTG – BCTG Acquisition Corp, 1.1%
- NTLA – Intellia Therapeutics Inc, 1.1%
- MBX – MBX Biosciences, Inc. Common Stock, 1.0%
- CGON – CG Oncology, Inc. Common stock, 1.0%
- GPCR – Structure Therapeutics Inc. American Depositary Shares, 1.0%
- GHRS – GH Research PLC, 1.0%
- ORIC – Oric Pharmaceuticals Inc, 1.0%
- CTMX – CytomX Therapeutics Inc, 1.0%
- TYRA_old – TYRA, 1.0%
- IRWD – Ironwood Pharmaceuticals Inc, 1.0%
- ANNX – Annexon Inc, 0.9%
- PGEN – Precigen Inc, 0.9%
- OMER – Omeros Corporation, 0.9%
- PRAX – Praxis Precision Medicines Inc, 0.9%
- QURE – Uniqure NV, 0.9%
- EWTX – Edgewise Therapeutics Inc, 0.9%
- IMNM – Immunome Inc, 0.9%
- UPB – Upstream Bio, Inc., 0.9%